Phosphaturic Mesenchymal Tumors with or without Phosphate Metabolism Derangements

Curr Oncol. 2023 Aug 8;30(8):7478-7488. doi: 10.3390/curroncol30080541.

Abstract

Phosphaturic mesenchymal tumors (PMT) are rare neoplasms, which can give rise to a multifaceted syndrome, otherwise called tumor-induced osteomalacia (TIO). Localizing these tumors is crucial to obtain a cure for the phosphate metabolism derangement, which is often the main cause leading the patient to seek medical help, because of invalidating physical and neuromuscular symptoms. A proportion of these tumors is completely silent and may grow unnoticed, unless they become large enough to produce pain or discomfort. FGF-23 can be produced by several benign or malignant PMTs. The phosphate metabolism, radiology and histology of these rare tumors must be collectively assessed by a multidisciplinary team aimed at curing the disease locally and improving patients' quality of life. This narrative review, authored by multiple specialists of a tertiary care hospital center, will describe endocrine, radiological and histological features of these tumors, as well as present surgical and interventional strategies to manage PMTs.

Keywords: FGF-23; TIO; orthopedics; phosphatonin; phosphaturic tumor; rare bone disease; surgery; tumor-induced osteomalacia.

Publication types

  • Review

MeSH terms

  • Hospitals
  • Humans
  • Osteomalacia*
  • Phosphates
  • Quality of Life
  • Soft Tissue Neoplasms*

Substances

  • Phosphates

Grants and funding

This research received no external funding.